Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Tirzepatide structure

Tirzepatide

Metabolic
Approved Research
95%
Low Risk
1/5

Dosing Protocol

Typical Dose 10 mg
Range 2.5 - 15 mg
Loading Phase 2.5 mg × 28 days
Maintenance 10 mg weekly

Pharmacokinetics

Half-Life 5.0 days
Onset 1.0 days
Peak 2.0 days
Duration 7.0 days
Bioavailability 80%
Primary Route Subcutaneous

Administration

Routes Subcutaneous
Injection Sites Abdomen, Thigh, Deltoid
Needle Gauge 30-31G
Syringe Type Standard
Timing same day weekly

Special Instructions

Inject same day each week. Can change injection day if at least 3 days since last dose. Rotate sites.